Search | Page 9 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes

    ... 24-month survival (especially among patients with refractory anemia or refractory anemia with excess blasts ). The magnitude of the cost of ...

    Research Article last updated 10/01/2012 - 9:41am.

  2. Immunosuppressive therapy for transplant-ineligible aplastic anemia patients

    ... in first-line treatment and management of relapsing and refractory patients with an emphasis on adult patients. Some promising new ...

    Research Article last updated 03/02/2015 - 1:04pm.

  3. hase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia

    ...

    Clinical Trial last updated 05/03/2016 - 10:41am.

  4. Total Marrow Irradiation for Refractory Acute Leukemia

    ...

    Clinical Trial last updated 05/02/2016 - 9:22am.

  5. Pathogenesis of MDS: An Overview of molecular and non-molecular aspects of the disease

    ... of 4.5 months) especially for patients who fail ( refractory /relapsed) HMT. The only potential curative treatment for MDS is ...

    Research Article last updated 05/12/2015 - 9:47am.

  6. Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

    ...

    Clinical Trial last updated 04/28/2016 - 1:17pm.

  7. Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed/Refractory Acute Leukemia or High-Risk MDS

    ...

    Clinical Trial last updated 04/28/2016 - 9:55am.

  8. Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

    ...

    Clinical Trial last updated 04/28/2016 - 9:51am.

  9. Anemia as the Main Manifestation of Myelodysplastic Syndromes

    ... Several new agents are under evaluation for ESA refractory /relapsed MDS patients, targeting different putative mechanisms ...

    Research Article last updated 12/02/2015 - 8:45am.

  10. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy

    ... by an external ambulatory infusion pump in patients with refractory anemia with excess blasts -1, -2, or, -t ...

    Research Article last updated 05/22/2014 - 10:23am.